Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

May 17, 2021

SELL
$6.6 - $9.0 $10,560 - $14,400
-1,600 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$6.47 - $7.9 $7,990 - $9,756
1,235 Added 338.36%
1,600 $10,000
Q3 2020

Nov 16, 2020

BUY
$6.55 - $8.83 $2,390 - $3,222
365 New
365 $2,000
Q1 2020

May 15, 2020

SELL
$3.61 - $8.6 $4,097 - $9,761
-1,135 Closed
0 $0
Q4 2019

Feb 14, 2020

BUY
$5.17 - $8.91 $5,867 - $10,112
1,135 New
1,135 $9,000
Q4 2018

Feb 14, 2019

SELL
$12.69 - $18.61 $17,093 - $25,067
-1,347 Closed
0 $0
Q3 2018

Nov 14, 2018

BUY
$18.04 - $26.41 $23,452 - $34,333
1,300 Added 2765.96%
1,347 $25,000
Q2 2018

Aug 14, 2018

BUY
$21.38 - $29.68 $705 - $979
33 Added 235.71%
47 $1,000
Q1 2018

May 15, 2018

BUY
$21.76 - $34.22 $304 - $479
14 New
14 $0

Others Institutions Holding CTMX

About CytomX Therapeutics, Inc.


  • Ticker CTMX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 65,950,200
  • Market Cap $55.4M
  • Description
  • CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...
More about CTMX
Track This Portfolio

Track Point72 Hong Kong LTD Portfolio

Follow Point72 Hong Kong LTD and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Point72 Hong Kong LTD, based on Form 13F filings with the SEC.

News

Stay updated on Point72 Hong Kong LTD with notifications on news.